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898Bleeding complications after percutaneous coronary inter-
vention (PCI) are common and are associated with an
increased short- and long-term risk of morbidity and
mortality as well as increased costs (1,2). Several bleeding
avoidance strategies (BAS), such as bivalirudin, radial
approach, and, in some studies, vascular closure devices, have
been proposed to reduce periprocedural bleeding among
higher-risk patient groups (3–6). Yet previous studies have
demonstrated a “risk-treatment” paradox with respect to the
use of BAS among patients undergoing PCI: BAS are used
the least among patients with the highest bleeding risk (7).
Among high-risk patients, such as those with ST-segment
elevation myocardial infarction, some of these BAS are
associated with reduced mortality (8,9), underscoring the
importance of applying BAS in patientsmost likely to beneﬁt.
Moreover, Medicare has begun considering peri-PCI
bleeding as a component of its Acute Care Episode
Demonstration Project, suggesting the growing importance
of bleeding as an indicator of quality.
Previous studies have identiﬁed patient factors associated
with bleeding in the context of acute coronary syndromeAbbreviations
and Acronyms
BARC = Bleeding Academic
Research Consortium
BAS = bleeding avoidance
strategies
BMI = body mass index
NCDR = National
Cardiovascular Data Registry(10,11); however, these studies
used a deﬁnition of bleeding
speciﬁc to the dataset in which
the models were developed and
did not include a broad pop-
ulation of patients undergoing
PCI. Given the importance of
PCI outcomes as performance
measures and the interest in public
reporting of PCI-related quality of
care (12), pre-procedural identiﬁ-cation of patients undergoing PCI who are at higher bleeding
risk could support more efﬁcient use of BAS to improve the
safety of PCI. Moreover, pre-procedural identiﬁcation could
facilitate better patient informed consent (13) and provide
risk-adjusted bleeding outcomes feedback to sites partici-
pating in quality improvement registries.
The National Cardiovascular Data Registry (NCDR)
CathPCI Registry is an ongoing contemporary quality
improvement registry of patients undergoing PCI in the
United States. The data elements recorded in the registry
undergo periodic review and are updated to support contin-
uous quality improvement. We previously published a model
predicting the risk of bleeding for patients undergoing PCI
using the data elements captured in the registry (14), but
the bleeding deﬁnition relied on site identiﬁcation of hemor-
rhagic events and was restrictive compared with bleeding
deﬁnitions used in other studies. For example, bleeding events
were not considered complications if they were not associated
with a prolonged hospital stay or a hemoglobin decrease of at
least 3 g/dl. In 2009, the CathPCI Registry implemented
a new data collection form with more detailed data elements
associated with bleeding events to capture importantcomplications that were not available in previous versions.
Using these data elements, a new CathPCI Registry post-
procedure bleeding deﬁnition was created, with which we
sought to: 1) deﬁne contemporary bleeding event rates; 2)
deﬁne major independent predictors of bleeding; and 3)
develop and validate a full pre-procedure risk predictionmodel
as well as a simple bedside additive risk prediction tool.
Methods
Study population. The CathPCI Registry is an initiative of
the American College of Cardiology and the Society for
Cardiovascular Angiography and Interventions and has been
previously described (15). This registry records data on
patient and hospital characteristics, clinical presentation,
hospital length of stay, treatments, and in-hospital outcomes
for PCI procedures from >1,000 sites across the United
States. The NCDR has a comprehensive data quality
program, including both data quality report speciﬁcations for
data capture and transmission, and an auditing program.
Dataset variables are determined and deﬁned by physician
work groups; data collection forms and dictionaries can be
found on the NCDR website (http://www.ncdr.com).
For this study, we included all PCI procedures performed
between February 2008 and April 2011 that had collected
data using version 4 of the CathPCI Registry data collection
form. Nonindex PCI procedures during the same hospital-
ization were excluded, as were patients who died the same
day as their procedure. In addition, we excluded patients
who had missing data on bleeding events and sites that re-
ported no bleeding events (Fig. 1).
Deﬁnitions and outcomes. The primary outcome for this
analysis was post-PCI bleeding. Using the updated data
collection form and the desire to improve the capture of
clinically important bleeding events, a panel of experts
amended the deﬁnition of bleeding as any of the following
occurring within 72 h after PCI or before hospital discharge
(whichever occurs ﬁrst): site-reported arterial access site
bleeding, which may be either external or a hematoma >10
cm for femoral access, >5 cm for brachial access, or >2 cm
for radial access; retroperitoneal, gastrointestinal, or geni-
tourinary bleeding; intracranial hemorrhage; cardiac tam-
ponade; post-procedure hemoglobin decrease of 3 g/dl in
patients with a pre-procedure hemoglobin level 16 g/dl; or
post-procedure nonbypass surgery–related blood transfusion
for patients with a pre-procedure hemoglobin level 8 g/dl.
This deﬁnition includes events such as intracranial hemor-
rhage, tamponade, hemoglobin decreases that account for
potential hemodilution, and transfusions that account for
severe anemia that were not included in the previous deﬁ-
nition. The deﬁnitions of the other data elements are
available at http://www.ncdr.com.
Statistical analysis. Categorical variables are summarized as
frequencies and percentages and compared with Pearson
Figure 1. Study Sample Selection Flow Diagram
The initial study population through the ﬁnal study population after applying
exclusions. Pts ¼ patients.
Table 1. Baseline Characteristics of the Development and Validation
Samples
Characteristics
Overall
(N ¼ 1,043,759)
Development
(n ¼ 834,696)
Validation
(n ¼ 209,063)
Demographic
Age yrs 65.0
(56.0–74.0)
64.0
(56.0–74.0)
65.0
(56.0–74.0)
Female 32.7 32.6 32.8
BMI, kg/m2 29.1
(25.7–33.3)
29.1
(25.7–33.3)
29.1
(25.7–33.3)
Medical conditions
Diabetes mellitus 35.9 35.9 35.9
Hypertension 81.8 81.8 81.9
Peripheral vascular
disease
12.4 12.4 12.4
Chronic kidney
disease
3.6 3.6 3.6
Previous PCI 40.3 40.3 40.3
Previous CABG 18.8 18.9 18.7
Median pre-procedure
Hb, g/dl
13.7
(12.4–14.9)
13.7
(12.4–14.9)
13.7
(12.4–14.9)
Procedural
Procedure status
Elective 45.2 45.2 45.1
Urgent 37.5 37.5 37.7
Emergent 17.0 17.0 16.9
Salvage 0.3 0.3 0.3
STEMI 16.0 16.0 15.9
Lytics before PCI
for STEMI
8.1 8.0 8.2
Shock 2.5 2.5 2.4
Cardiac arrest within
24 h of PCI
1.7 1.7 1.7
Hospital
Beds 410.0
(283.0–571.0)
410.0
(283.0–571.0)
409.0
(282.0–569.0)
University hospital 11.3 11.3 11.3
Annual PCI cases 726.0
(445.1–1,177.9)
726.6
(445.1–1,183.1)
726.6
(448.0–1,177.9)
Values are median (25th–75th percentile) or %. All p values >0.05.
BMI ¼ body mass index; CABG ¼ coronary artery bypass grafting; Hb ¼ hemoglobin;
PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial
infarction.
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899chi-square tests. Continuous variables are summarized as
median (interquartile range) and compared using Wilcoxon
rank sum tests. Ordinal variables were tested using a chi-
square test based on the rank of the group mean score.
The study population was randomly split into a develop-
ment sample consisting of 80% of admissions and a valida-
tion sample consisting of the remaining 20% of admissions.
Baseline patient characteristics and variables from diagnostic
catheterization were considered candidate variables. Candi-
date variables had <0.5% missing data except for estimated
glomerular ﬁltration rate (7.8%), pre-procedure hemoglobin
level (9.5%), and ejection fraction (29.4%). Missing values
were imputed to the lower risk group for discrete variables
and replaced with sex-speciﬁc medians for body mass index
(BMI), sex, and renal failure/dialysis–speciﬁc medians for
estimated glomerular ﬁltration rate, median value for
hemoglobin, and congestive heart failure/cardiogenic shock/
previous myocardial infarction–speciﬁc medians for ejection
fraction. We used logistic regression with backward selection
to stay criterion of p < 0.05 to develop a model predicting
post-PCI bleeding. Variables that showed nonlinear asso-
ciations with the outcome were transformed using splines.
We developed a full post-PCI bleeding model using all
potential predictive variables. We also developed a risk
prediction score by taking the regression coefﬁcients from
the pre-procedure model and assigning them an integer
weighted to the comparative odds ratio associated with the
risk factors (16). Covariates selected for the risk score were
those with a chi-square >500. An individual patient’s
bleeding risk score is the sum of their integer weights.
Patients were deﬁned as at low, medium, and high risk ofbleeding based on the predicted risk of bleeding derived
from the prediction score. Patients with a predicted risk of
bleeding at or below the 25th percentile probability were
considered low risk, patients with a predicted risk of
bleeding between the 25th and 75th percentile probability
were considered moderate risk, and patients with a predicted
risk of bleeding at or above the 75th percentile probability
were considered high risk.
The C-statistic was used to compare discrimination
between models and in clinical subgroups of interest
including patients with ST-segment elevation myocardial
infarction, females, those older than 70 years of age, those
Table 2. In-hospital Bleeding Rates Overall and in Pre-speciﬁed Subgroups
in the Development and Validation Samples
Group
Overall
(N ¼ 1,043,759)
Development
(n ¼ 834,696)
Validation
(n ¼ 209,063)
All patients 5.8 5.8 5.8
STEMI 14.1 14.2 14.0
Females 8.6 8.7 8.5
Age >70 yrs 7.5 7.5 7.5
Diabetes 5.9 6.0 5.9
Excluding in-hospital CABG 5.4 5.4 5.4
Values are %.
Abbreviations as in Table 1.
Table 3. The Full Model
Category OR 95% CI Chi-Square
Demographic characteristics and
medical history
Female vs. male 1.97 1.93–2.02 4,045.30
Dialysis vs. no disease 1.88 1.80–1.95 975.02
Moderate chronic kidney disease
(GFR ¼ 30–44 ml/min) vs. no disease
1.68 1.62–1.73 918.89
Previous PCI 0.74 0.72–0.76 726.13
BMI (when BMI  30 kg/m2)* 0.96 0.96–0.97 594.60
Mild chronic kidney disease
(GFR ¼ 45–59 ml/min) vs. no disease
1.34 1.31–1.38 487.83
Heart Failure NYHA class IV within
2 weeks Heart failure NYHA
class IV within 2 weeks vs. no heart
failure within 2 weeks
1.63 1.56–1.70 458.03
Age (70 yrs)* 1.02 1.01–1.02 456.10
Chronic lung disease 1.23 1.19–1.26 241.87
Peripheral vascular disease 1.19 1.15–1.22 139.27
NYHA functional class IV HF within
2 weeks before PCI vs. NYHA
functional class<IV
1.17 1.13–1.21 76.74
Cerebrovascular disease 1.13 1.10–1.16 74.81
Age (>70 yrs)* 1.01 1.00–1.01 51.20
Insulin requiring diabetes mellitus vs.
no diabetes
1.09 1.06–1.13 32.29
Presenting characteristics and PCI status
Shock within 24 h before and at start
of PCI or Salvage procedure
6.02 5.67–6.39 3,511.54
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900with diabetes mellitus, and those who did not undergo
in-hospital coronary artery bypass grafting. Calibration plots
were used to access goodness of ﬁt. A p value <0.05 was
considered statistically signiﬁcant. All statistical tests were
2 sided. All statistical analyses were performed at the Duke
Clinical Research Institute using SAS software (version 9.2,
SAS Institute, Cary, North Carolina) and Stata version
11 (StataCorp LP, College Station, Texas).
Ethical considerations. The Institutional Review Board of
Duke University Medical Center approved this analysis and
determined that it met the deﬁnition of research not
requiring informed consent.Emergent procedure 2.88 2.76–3.00 2,557.14
Shock within 24 h or at start of PCI 4.39 4.13–4.66 2,334.84
Urgent procedure 1.50 1.46–1.54 948.41
Shock within 24 h and at start of PCI 5.22 4.56–5.98 571.96
Cardiac arrest within 24 h of PCI 1.75 1.66–1.83 533.55
Lytics before PCI for STEMI 1.12 1.04–1.19 10.11
Laboratory values
Pre-PCI Hb (Hb 13 g/dl)* 0.80 0.79–0.81 2,300.92
Pre-PCI Hb (Hb >13 g/dl)* 1.11 1.10–1.12 621.50
Procedural characteristics
2- or 3-vessel disease vs. no disease
or 1-vessel disease
1.23 1.20–1.25 397.13
STEMI 1.45 1.40–1.50 376.49
SCAI lesion class II or III 1.25 1.22–1.28 330.45
SCAI lesion class IV 1.43 1.37–1.49 301.23
Pre-procedure TIMI ﬂow grade ¼ 0 1.24 1.20–1.29 151.28
Left main PCI 1.43 1.35–1.51 149.45
Subacute stent thrombosis 1.61 1.44–1.81 67.12
Proximal LAD PCI 1.10 1.07–1.12 51.43
*Variables transformed using splines
CI ¼ conﬁdence interval; GFR ¼ glomerular ﬁltration rate; HF ¼ heart failure; LAD ¼ left
anterior descending; NYHA ¼ New York Heart Association; OR ¼ odds ratio; SCAI ¼ Society for
Cardiovascular Angiography and Intervention; TIMI ¼ Thrombolysis In Myocardial Infarction;
other abbreviations as in Table 1.Results
Study sample. Between February 2008 and April 2011,
1,059,474 PCI procedures were performed at 1,232 sites and
had data entered into version 4 of the CathPCI Registry
data collection form. After applying exclusion criteria,
1,043,759 procedures from 1,142 sites remained (Fig. 1).
Table 1 displays the baseline patient, procedure, and hospital
characteristics of the development and validation samples.
There were 60,194 PCI procedures that had post-procedure
bleeding, yielding a post-PCI bleeding event rate of 5.8%.
Of these events, 32% were site-reported at a speciﬁc
anatomic location, whereas 44.6% were detected due to
a pre- to post-procedure hemoglobin decrease, 21.8% by
a blood transfusion, 1% by cardiac tamponade, and 0.6%
were intracranial hemorrhage events.
Risk factors for in-hospital bleeding. Table 2 displays the in-
hospital bleeding rates for the overall development and
validation samples, as well as the rates for each pre-speciﬁed
subgroup within the samples. The full model, which
includes 33 variables, is displayed in Table 3. The most
predictive factors, according to their chi-square, were female
sex followed by shock or salvage PCI. In contrast, non-
insulin-requiring diabetes mellitus was the least predictive.
Several variables required transformation with splines such
that the relationship with bleeding changed according toknots at speciﬁc values. Pre-procedure hemoglobin value,
BMI, and age all had nonlinear associations with bleeding
and required transformation. Table 4 shows the bedside
NCDR bleeding risk score derived from the pre-procedure
Table 4. NCDR CathPCI Bleeding Risk Score
Variable Score
STEMI No Yes
0 15
Age, yrs <60 60–70 71–79 80
0 10 15 20
BMI <20 20–30 31–39 40
15 5 0 5
Previous PCI No Yes
10 0
Chronic kidney disease No Mild Moderate Dialysis
0 10 25 30
Shock No Yes
0 35
Cardiac arrest within 24 h No Yes
0 15
Female No Yes
0 20
Hb Hb <13 13 Hb <15 Hb 15
5 0 10
PCI status Elective Urgent Emergency/salvage
0 20 40
Abbreviations as in Table 1.
Table 5. Risk of Bleeding Based on Point Totals From the
NCDR CathPCI Registry Bleeding Risk Score
Total Points Risk of Bleeding, %
0 0.90
5 1.10
10 1.30
15 1.50
20 1.70
25 2.00
30 2.30
35 2.70
40 3.10
45 3.60
50 4.20
55 4.90
60 5.60
65 6.50
70 7.50
75 8.60
80 9.90
85 11.40
90 13.10
95 14.90
100 17.00
105 19.30
110 21.80
115 24.60
120 27.50
125 30.70
130 34.10
135 37.60
140 41.30
145 45.10
150 49.00
155 52.80
160 56.60
165 60.40
170 64.00
175 67.50
180 70.80
185 73.90
190 76.80
195 79.40
200 81.80
205 84.00
210 86.00
NCDR ¼ National Cardiovascular Data Registry.
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901model. Using these 10 variables and the scoring system, the
risk of post-PCI bleeding can be estimated by summing the
point scores between 0 and 210 (Table 5, Fig. 2).
Model performance. The full bleeding risk model had good
discrimination in both the development and validation
samples (c-index, development sample 0.78; validation
sample 0.77). Table 6 lists the c-indexes of the full model
and the risk score in the overall development and validation
samples, as well as in pre-speciﬁed subgroups. The c-indexes
for the subgroups ranged from 0.70 to 0.78. The model
calibration plot for the full model is shown in Figure 3.
There was high concordance between the risk predicted by
the models and the observed bleeding events. Model cali-
bration plots for the pre-speciﬁed subgroups are shown in
the Online Appendix. There was a high level of concordance
among these subgroups as well.
Discussion
Bleeding remains one of the most common complications of
PCI. Accordingly, as part of its quality improvement efforts,
the NCDR seeks to improve its data collection and update
its risk models by leveraging new data elements and
improving bleeding deﬁnitions to capture a range of addi-
tional clinically important variables. These new models can
be used to improve the safety of PCI by enabling the
prospective identiﬁcation of patients who would beneﬁt
most from BAS and by creating the infrastructure to support
risk-adjusted provider feedback reports.Using our updated bleeding deﬁnition,w1 in 20 patients
(5.8%) were observed to have a bleeding event. This rate is
higher than previously reported (2.4%) and reﬂects the
inclusion of bleeding complications (such as tamponade and
transfusions in clinically appropriate groups) that were not
included in the previous deﬁnition, but which enabled
broader estimates of clinically important bleeding to be
Figure 2. Risk of Post-Percutaneous Coronary Intervention Bleeding
Based on the Bedside Bleeding Risk Prediction Score
The predicted risk of in-hospital bleeding among patients determined to be at
low, medium, or high risk of bleeding based on the bedside bleeding risk
score. Scores of 25 are low risk, scores 25 to 65 are medium risk, and scores
>65 are high risk.
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902generated. The bleeding rate reported in our study is also
more consistent with the rate reported in clinical trials, such
as the ACUITY (Acute Catheterization and Urgent Inter-
vention Triage Strategy) trial, where the rate of bleeding
among patients treated with glycoprotein IIb/IIIa inhibitors
was 5.3% to 5.7% (17).
Studies indicate that the reported rate of bleeding is
highly dependent on the deﬁnition used (18); a standardized
bleeding deﬁnition, called the Bleeding Academic Research
Consortium (BARC) deﬁnition, was recently proposed for
clinical trials of patients with acute coronary syndrome or
those undergoing PCI (19). The BARC deﬁnition includes
many of the elements used in the current CathPCI Registry
bleeding deﬁnition, but also relies heavily on adjudication.
Although the size and scope of the CathPCI Registry
makes adjudication of bleeding events impractical, the new
bleeding deﬁnition is consistent with the major componentsTable 6. c-Indexes of the Full Model and Risk Score Models in the Overall Datas
Group
n
Development
Sample
Validation
Sample
D
Overall 834,696 209,063
STEMI 133,649 33,311
Women 272,357 68,540
Age >70 yrs 275,089 69,015
Diabetes 299,402 75,003
Excluding in-hospital CABG 824,414 205,510
Abbreviations as in Table 1.of the BARC deﬁnition. An ongoing randomized clinical
trial, the SAFE-PCI (Study of Access site For Enhance-
ment of PCI for Women [NCT01406236]), is using the
CathPCI Registry as a platform for data collection and has
BARC type 2 or greater bleeding as the primary endpoint.
This study will provide estimates of the correlation between
BARC-deﬁned bleeding and the updated CathPCI Registry
deﬁnition of bleeding.
Importantly, a number of patient characteristics were
strongly associated with periprocedural bleeding.Many of the
predictive factors that we identiﬁed have been shown in other
studies to be predictive of bleeding events. For example,
female sex is consistently associated with an increased risk of
bleeding (20), as are other variables like age, renal function,
and BMI (21). In addition to these factors, we also identiﬁed
unique variables not present in other bleeding risk models,
such as pre-procedure hemoglobin level, cardiac arrest, shock,
and clinical status (e.g., salvage procedures). For the fullmodel
that will be used to support risk-adjusted hospital compari-
sons, the addition of such variables is a signiﬁcant advantage
over previous models that use clinical trial data where the
acuity of clinical presentation is generally not as severe. The
inclusion of these variables minimizes the risk that hospitals
that disproportionately care for patients with these high-risk
characteristics would not be unduly penalized. Thismodel can
be used to risk-adjust post-PCI bleeding rates for the centers
participating in the CathPCI Registry, identify leaders and
laggards, and ultimately improve the safety of PCI by
encouraging the adoption of BAS at centers that have higher-
than-expected risk-adjusted bleeding rates. For example,
previous studies have shown substantially greater absolute risk
reductions with BAS use among patients with higher bleeding
risks, previously deﬁned as >1% (14). Corresponding
thresholds with the new bleeding deﬁnition would be a risk of
2.0% (integer score25),>2.0%,6.5% (integer bleeding
risk score of 25 to 65), and high risk representing risks>6.5%
(integer bleeding risk score >65). The use of the CathPCI
Registry bleeding risk scoremay encourage greater adoption of
bivalirudin, vascular closure devices, or radial approach among
patients in these higher-risk categories. This may beet and in Pre-Speciﬁed Subgroups
Full Model Risk Score
evelopment
Sample
Validation
Sample
Development
Sample
Validation
Sample
0.78 0.77 0.76 0.75
0.71 0.71 0.70 0.70
0.74 0.74 0.73 0.72
0.76 0.76 0.74 0.74
0.78 0.78 0.76 0.76
0.79 0.78 0.76 0.76
Figure 3. Model Calibration Plot for the Full Model
The observed versus the predicted bleeding rates and 95% conﬁdence
intervals for 10 equally sized risk groups.
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903particularly important given the interest in public reporting
of PCI-related outcomes (12). The distribution of risk
using the new bleeding deﬁnition potentially broadens the
proportion of patients who might beneﬁt from BAS imple-
mentation, but future comparative effectiveness studies are
needed to conﬁrm this hypothesis. The bedside risk score
that we developed, using 10 key variables, has further utility
by facilitating pre-procedure identiﬁcation of patients at
high risk of bleeding, as well as informing the consent
process (13).
Study limitations. First, in many states, participation in the
CathPCIRegistry is voluntary; therefore, this registrymay not
be completely representative of all PCI procedures performed
in the United States. Nevertheless, the CathPCI Registry is
the largest ongoing contemporary registry of PCI and there
are no a priori reasons to believe that the associations between
patient characteristics and periprocedural bleeding would
differ among hospitals that do and do not participate in the
NCDR. Second, the new deﬁnition of bleeding still includes
site-identiﬁed bleeding complication data, although these
data have objective deﬁnitions, sites may vary in their
threshold for reporting these events. Nevertheless, the deﬁ-
nition now also includes blood transfusion, hemoglobin
decreases, and intracranial hemorrhage, thereby making it
likely to detect the most clinically signiﬁcant bleeding events.
The use of blood transfusion in the registry may not neces-
sarily reﬂect clinical bleeding, and its use is controversial in
patients with coronary artery disease. Although some may
argue that other physicians involved in patient care may be
ordering “unnecessary” blood transfusions, the limitation of
the new deﬁnition to only include those transfusions that
occur in patients with hemoglobin values >8 mg/dl is
congruent with previous data showing harm from transfusions
in this population (22,23).Conclusions
Using data from the NCDR CathPCI Registry, we updated
the deﬁnition of bleeding to capture hemorrhagic events
previously excluded and developed and validated contem-
porary predictive and risk-adjustment models for post-PCI
bleeding. The models had good operating characteristics in
the overall dataset of patients undergoing PCI, as well as
among high-risk subgroups. This model will serve as the
basis for providing risk-adjusted feedback on bleeding rates
for sites participating in the CathPCI Registry, and the
bedside bleeding risk score can facilitate the use of BAS in
patients most likely to beneﬁt.
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